

Publikationsliste Dr. med. Ludwig Fischer von Weikersthal

2022

Resilience in cancer patients and how it correlates with demographics, psychological factors and lifestyle

Lara Festerling · J. Buentzel · [L. Fischer von Weikersthal](#) · C. Junghans · B. Zomorodbakhsch · C. Stoll · F.-J. Prott · S. Fuxius · O. Micke · A. Richter · D. Sallmann · J. Huebner · Catalina Hoppe

Research Square <https://doi.org/10.21203/rs.3.rs-1610739/v1>

Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial

Annika Kurreck · Volker Heinemann · [Ludwig Fischer von Weikersthal](#) · Thomas Decker · Florian Kaiser · Jens Uhlig · Michael Schenk · Jens Freiberg-Richter · Bettina Peuser · Claudio Denzlinger · Ullrich Graeven · Kathrin Heinrich · Swantje Held · Arndt Stahler · Annabel Helga Sophie Alig · Ivan Jelas · Jobst C. von Einem · Sebastian Stintzing · Clemens Giessen-Jung · Dominik P. Modest

Front. Oncol. 12:751453. doi: 10.3389/fonc.2022.751453

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy

Annabel H S Alig · Volker Heinemann · Michael Geissler · [Ludwig Fischer von Weikersthal](#) · Thomas Decker · Kathrin Heinrich · Swantje Held · Lena Weiss · Laura E Fischer · Nicolas Moosmann · Arndt Stahler · Ivan Jelas · Annika Kurreck · Jobst C von Einem · Anke C Reinacher-Schick · Andrea Tannapfel · Clemens Giessen-Jung · Sebastian Stintzing · Dominik P Modest

Cancers (Basel). 2022 Jan 21;14(3):526. doi: 10.3390/cancers14030526.

2021

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - the PARLIM trial (AIO KRK 0314)

Dominik Modest, Karthaus Meinolf, Stefan Kasper, Nicolas Moosmann, Verena Keitel, Alexander Kiani, Jens Uhlig, Lutz Jacobasch, [Ludwig Fischer von Weikersthal](#), Martin Fuchs, Florian Kaiser, Christian Lerchenmüller, Dagmar Sent, Christian Junghanss, Swantje Held, Sylvie Lorenzen, Klaus Kaczirek, Andreas Jung, Sebastian Stintzing, and Volker Heinemann

Meeting Abstract | 2021 ASCO Annual Meeting I

Mutational profiles of metastatic colorectal cancer patients treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection of metastases (AIO KRK 0306; FIRE-3)

Arndt Stahler · Volker Heinemann · Jobst C. von Einem · C. Benedikt Westphalen · Kathrin Heinrich · Laura Schlieker · Ivan Jelas · Annabel Helga Sophie Alig · Laura Elisabeth Fischer · Lena Weiss · Annika Kurreck · Dominik P. Modest · [Ludwig Fischer von Weikersthal](#) · Thomas Decker · Alexander Kiani · Markus Moehler · Florian Kaiser · Thomas Kirchner · Andreas Jung · Sebastian Stintzing

Int J Cancer. 2021 Dec 1;149(11):1935-1943. doi: 10.1002/ijc.33747. Epub 2021 Jul 31.

HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study

Ivonne Haffner, PhD · Katrin Schierle, MD · Elba Raimu´ndez, PhD · Birgitta Geier, PhD · Dieter Maier, PhD · Jan Hasenauer, PhD · Birgit Luber, PhD · Axel Walch, MD · Katharina Kolbe, MD · Jorge Riera Knorrenschild, MD ·

Albrecht Kretschmar, MD · Beate Rau, MD · [Ludwig Fischer von Weikersthal, MD](#) · Miriam Ahlborn, PD · Gabriele Siegler, MD · Stefan Fuxius, MD · Thomas Decker, MD · Christian Wittekind, MD · Florian Lordick, MD

ascopubs.org by 95.91.233.8 on March 27, 2021 from 095.091.233.008

Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3)

Arndt Stahler · Volker Heinemann · Julian Walter Holch · Jobst Christian von Einem · Christoph Benedikt Westphalen · Kathrin Heinrich · Laura Schlieker · Ivan Jelas · Annabel Helga Sophie Alig · Laura Elisabeth Fischer · Lena Weiss · Dominik Paul Modest · [Ludwig Fischer von Weikersthal](#) · Thomas Decker · Alexander Kiani · Markus Moehler · Florian Kaiser · Thomas Kirchner · Andreas Jung · Sebastian Stintzing

International Journal of Cancer DOI: 10.1002/ijc.33747 <https://doi.org/10.1002/ijc.33747>

Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)

Lian Liu · Nicole Tonya Erickson · Ingrid Ricard · [Ludwig Fischer von Weikersthal](#) · Markus M. Lerch · Thomas Decker · Alexander Kiani · Florian Kaiser · Tobias Heintges · Christoph Kahl · Frank Kullmann · Werner Scheithauer · Hartmut Link · Heinz-Gert Höffkes · Markus Moehler · Alena Britta Gesenhues · Sebastian Theurich · Marlies Michl · Dominik P. Modest · Hana Algül · Sebastian Stintzing · Volker Heinemann · Julian W. Holch

International Journal of Cancer: <https://doi.org/10.1002/ijc.33775>

Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).

Sebastian Stintzing · Kathrin Heinrich · David Tougeron · Dominik Paul Modest · Ingo Schwaner · Jan Euker · Rudolf Pihusch · Martina Stauch · Florian Kaiser · Christoph Kahl · Meinolf Karthaus · Christian Mueller · Christof Burkart · Anke C. Reinacher-Schick · Stefan Kasper · [Ludwig Fischer von Weikersthal](#) · Beate Krammer-Steiner · Gerald W. Prager · Julien Taieb · Volker Heinemann

2021 ASCO Annual Meeting

Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIOKRK-0110)*

Kathrin Heinrich · Dominik P. Modest · Ingrid Ricard · [Ludwig Fischer von Weikersthal](#) · Thomas Decker · Florian Kaiser · Ullrich Graeven · Jens Uhlig · Michael Schenk · Jens Freiberg-Richter · Bettina Peuser · Claudio Denzlinger · Clemens Giessen-Jung · Arndt Stahler · Marlies Michl · Swantje Held · Andreas Jung · Thomas Kirchner · Sebastian Stintzing · Volker Heinemann

European Journal of Cancer 147 (2021) 128e139

Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method

M.Haas · D.T.Waldschmidt · M.Stahl · A.Reinacher-Schick · J.Freiberg-Richter · [L.Fischer von Weikersthal](#) · F.Kaiser · S.Kanzler · N.Frickhofen · T.Seufferlein · T.Dechow · R.Mahlberg · P.Malfertheiner · G.Illerhaus · S.Kubicka · A.Abdul-Ahad · R.Snijder · S.Kruger · V.Heinemann

Eur J Cancer Volume 146, March 2021, Pages 95-106

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

Volker Heinemann · [Ludwig Fischer von Weikersthal](#) · Thomas Decker · Alexander Kiani · Florian Kaiser · Salah-Edin Al-Batran · Tobias Heintges · Christoph Lerchenmüller · Christoph Kahl <https://www.nature.com/articles/s41416-020-01140-9 - Aff9> · Gernot Seipelt <https://www.nature.com/articles/s41416-020-01140-9 - Aff10> · Frank Kullmann <https://www.nature.com/articles/s41416-020-01140-9 - Aff11> · Markus Moehler · Werner Scheithauer · Swantje Held · Lisa Miller-Phillips · Dominik Paul Modest <https://www.nature.com/articles/s41416-020-01140-9 - Aff1> · Andreas Jung · Thomas Kirchner <https://www.nature.com/articles/s41416-020-01140-9 - Aff15> · Sebastian Stintzing

British Journal of Cancer volume 124, pages587–594(2021)

2020

First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study

Tobias Dechow · Jorge Riera-Knorrenschild · Björn Hackanson · Jan Janssen · Holger Schulz · Marco Chiabudini · [Ludwig Fischer von Weikersthal](#) · Stephan Budweiser · Axel Nacke · Dagmar Tauscher · Manfred Welslau · Karin Potthoff

Cancer Med. 2021 Nov;10(22):8127-8137. doi: 10.1002/cam4.4310. Epub 2021 Oct 20.

Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

Arndt Stahler · Sebastian Stintzing · Dominik P. Modest · Ingrid Ricard · Clemens Giessen-Jung · Christine Kapaun · Boryana Ivanova · Florian Kaiser · [Ludwig Fischer von Weikersthal](#) · Nicolas Moosmann · Andreas Schalhorn · Martina Stauch · Alexander Kiani · Swantje Held · Thomas Decker · Markus Moehler · Jens Neumann · Thomas Kirchner · Andreas Jung · Volker Heinemann

AACRJournals.org 2020; DOI: 10.1158/1078-0432.CCR-20-2748

Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIOKRK0110, XELAVIRI study)

Annika Kurreck · Volker Heinemann · [Ludwig Fischer von Weikersthal](#) · Thomas Decker · Florian Kaiser · Jens Uhlig · Michael Schenk · Jens Freiberg-Richter · Bettina Peuser · Claudio Denzlinger · Ullrich Graeven · Ingo Schwaner · Arndt Stahler · Kathrin Heinrich · Andreas Jung · Swantje Held · Jobst C. von Einem · Sebastian Stintzing · Clemens Giessen-Jung · Dominik P. Modest

European Journal of Cancer 137 (2020) 81e92

Quality of Life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer (PARAGON) registry

Salah-Eddin Al-Batran · Ralf-Dieter Hofheinz · Alexander Reichart · Claudia Pauligk · Caroline Schönherr · Rudolf Schlag · Gabriele Siegler · Steffen Dörfel · Michael Koenigsmann · Mark-Oliver Zahn · Jörg Schubert · Ali Aldaoud · Heinz-Gert Höffkes · Holger Schulz · Lars Hahn · Jens Uhlig · Wolfgang Blau · Martina Stauch · Jörg Weniger · Martin Wolf · Lutz Jacobasch · Stephan Bildat · Jürgen Wehmeyer · Nils Homann · Jörg Trojan · Oliver Waidmann

· Thomas Fietz · Hans-Peter Feustel · Matthias Groschek · Jan Wierecky · Karin Waibel · Stefan Mahlmann · Uwe Schwindel · Uwe Peters · Gunter Schuch · Daniel Pink · Henning Eschenburg · Marcus-A Wörns · Hans-Detlev Harich · [Ludwig Fischer von Weikersthal](#) · Klaus-Ulrich Däßler · Dirk M Behringer · Helmut Messmann · Albrecht Kretschmar · Eike Gallmeier · Helmut Forstbauer · Volker Kunzmann · Jens Papke · Petra Büchner-Stedel · Ursula Vehling-Kaiser · Christoph Springfeld · Arndt Vogel · Thomas J Ettrich · Marina Schaaf · Gerrit Zur Hausen · Thorsten Oliver Götze

Int J Cancer Actions. 2020 Oct 10. doi: 10.1002/ijc.33336. Online ahead of print
DOI: 10.1002/ijc.33336

Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer - results from the FIRE-3 (AIO KRK-0306) study

Schulz, Christoph · Heinemann, Volker · Heinrich, Kathrin · Haas, Michael · Holch, Julian W. · Fraccaroli, Alessia · Held, Swantje · von Einem, Jobst C. · Modest, Dominik P. · [Fischer von Weikersthal, Ludwig](#) · Kullmann, Frank · Moehler, Markus · Scheithauer, Werner · Jung, Andreas · Stintzing, Sebastian

Anti-Cancer Drugs: July 3, 2020 - doi: 10.1097/CAD.0000000000000965

Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306) -

J.W. Holch · S. Held · S. Stintzing · [L. Fischer von Weikersthal](#) · T. Decker · A. Kiani · F.Kaiser · T. Heintges · C. Kahl · F. Kullmann · W. Scheithauer · M. Moehler · J.C. von Einem · M. Michl · V. Heinemann ·

Annals of Oncology January 06, 2020 Volume 31, ISSUE 1, P72-78, January 01, 2020
DOI: <https://doi.org/10.1016/j.annonc.2019.10.001>

2019

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah-Eddin Al-Batran · Nils Homann · Claudia Pauligk · Thorsten O Goetze · Johannes Meiler · Stefan Kasper · Hans-Georg Kopp · Frank Mayer · Georg Martin Haag · Kim Luley · Udo Lindig · Wolff Schmiegel · Michael Pohl · Jan Stoeilmacher · Gunnar Folprecht · Stephan Probst · Nicole Prasnikar · Wolfgang Fischbach · Rolf Mahlberg · Jörg Trojan · Michael Koenigsmann · Uwe M Martens · Peter Thuss-Patience · Matthias Egger · Andreas Block · Volker Heinemann · Gerald Illerhaus · Markus Moehler · Michael Schenk · Frank Kullmann · Dirk M Behringer · Michael Heike · Daniel Pink · Christian Teschendorf · Carmen Löhr · Helga Bernhard · Gunter Schuch · Volker Rethwisch · [Ludwig Fischer von Weikersthal](#) · Jörg T Hartmann · Michael Kneba · Severin Daum · Karsten Schulmann · Jörg Weniger · Sebastian Belle · Timo Gaiser · Fuat S Oduncu · Martina Güntner · Wael Hozaeel · Alexander Reichart · Elke Jäger · Thomas Kraus · Stefan Mönig · Wolf O Bechstein · Martin Schuler · Harald Schmalenberg · Ralf D Hofheinz · on behalf of the FLOT4-AIO Investigators

Lancet. 2019 May 11;393(10184):1948-1957.

DIHBH-VMAT for Consolidation RT in Mediastinal B-NHL can Significantly Reduce Dose to OAR Report of TWO Cases

Antje Fahrig · Th. Koch · CH Heinde · M Lenhart · [L Fischer von Weikersthal](#)

Radiol Imaging Technol 2019, 5:044

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study – XELAVIRI (AIO KRK0110)

Dominik P Modest · Ludwig Fischer von Weikersthal · Thomas Decker · Ursula Vehling-Kaiser · Jens Uhlig · Michael Schenk

Journal of Clinical Oncology 37/2019 1 (January 1 2019) 22-32

2018

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.

Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, Engelke A, Fink AM, Fischer K, Tausch E, Seiler T, Fischer von Weikersthal L, Hebart H, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M.

Lancet Oncol. 2018 Sep;19(9):1215-1228.

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.

Haas M · Siveke JT · Schenk M · Lerch MM · Caca K · Freiberg-Richter J · von Weikersthal L · Kullmann F · Reinacher-Schick A · Fuchs M · Kanzler S · Kunzmann V · Ettrich TJ · Kruger S · Westphalen CB · Held S · Heinemann V · Boeck S.

Eur J Cancer. 2018 Mar 14;94:95-103

Interim analysis of the non-interventional study (NIS) „StepUp“ assessing initial dosing schedules of oral vinorelbine in patients with advanced non-small lung cancer (NSCLC) or metastatic breast cancer (MBC) in clinical routine in Germany and Austria

de Wit M · Angermeier, S · Groschek, M · von Weikersthal LF · Roitner, F · Strittmatter, HJ · Tome, O · Petru, E · Rauter, M · Randerath, W · Abenhardt, W · Bischoff, J · Egert, M · Eschenburg, H · Krause, G · Schem, C · Edlich, B · Singer, C · Jakob, A

Oncol RES TREAT, 2018, 41: 2296-5270

Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.

Holch JW · Ricard · Stintzing S · Fischer von Weikersthal L · Decker T · Kiani A · Vehling-Kaiser U · Al-Batran SE · Heintges T · Lerchenmüller C · Kahl C · Kullmann F · Scheithauer W · Scholz M · Müller S · Link H · Rost A · Höffkes HG · Moehler M · Lindig RU · Miller-Phillips L · Kirchner T · Jung A · von Einem JC · Modest DP · Heinemann V.

Int J Cancer. 2018 Mar 1;142(5):1047-1055

2017

Central validation of HER2 status to determine heterogeneity of marker expression in HER2-positive gastric cancer (GC).

I. Haffner · B. Luber · D. Maier · A. Kretschmar · L. Fischer von Weikersthal · M. Ahlborn · J. Riera-Knorrenschild · B. Rau · F. Weissinger · S. Fuxius · S. Neumann · T. Decker · K. Schierle · C. Wittekind · F. Lordick

http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.12

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE-3 (AIO KRK-0306) trial.

S. Stintzing · P. Wirapati · H-J. Lenz · D. Neureiter · L. Fischer von Weikersthal · T. Decker · A. Kiani · U. Vehling-Kaiser · S-E. Al-Batran · T. Heintges · C. Kahl · F. Kullmann · M. Moehler · W. Scheithauer · S. Held · D. Modest · A. Jung · T. Kirchner · S. Tejpar · V. Heinemann

http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3510

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.

Haas M · Siveke JT · Schenk M · Lerch MM · Caca K · Freiberg-Richter J · Fischer von Weikersthal L · Kullmann F · Reinacher-Schick A · Fuchs M · Kanzler · Kunzmann V · Ettrich TJ · Kruger S · Westphalen C · Held S · Heinemann V · Boeck S.

Eur J Cancer. 2018 Mar 14;94:95-103. doi: 10.1016/j.ejca.2018.02.008.

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).

Modest DP · Ricard I · Stintzing S · Fischer von Weikersthal L · Decker T · Kiani A · Vehling-Kaiser U · Al-Batran SE · Heintges T · Kahl C · Seipelt G · Kullmann F · Scheithauer W · Moehler M · Westphalen CB · Holch JW · von Einem JC · Held S · Heinemann V · for FIRE-3/AIOKRK0306-investigators.

Eur J Cancer. 2017 Oct;84:262-269. doi: 10.1016/j.ejca.2017.07.030. Epub 2017 Aug 23

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306).

Modest DP · Stintzing S · von Weikersthal LF · Decker T · Kiani A · Vehling-Kaiser U · Al-Batran SE · Heintges T · Kahl C · Seipelt G · Kullmann F · Scheithauer W · Moehler M · Holch J · von Einem JC · Held S · Heinemann V.

Oncotarget. 2017 Nov 11;8(62):105749-105760. doi: 10.18632/oncotarget.22396. eCollection 2017 Dec 1.

Impact of BRAF and RAS mutation on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

S. Stintzing · L. Miller-Phillips · DP. Modest · L. Fischer von Weikersthal · T. Decker · A Kiani · U. Vehling-Kaiser · S.-E. Al-Batran · T. Heintges · G. Seipelt · F. Kullmann · M. Stauch · S. Held · M. Moehler · A. Jagenburg · T. Kirchner · A. Jung · FIRE-3 Investigator

Eur J Cancer. 2017 Jul;79:50-60. doi: 10.1016/j.ejca.2017.03.023. Epub 2017 Apr 29

Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.

Stahler A · Heinemann V · Neumann J · Crispin A · Schalhorn A · Stintzing S · Giessen-Jung C · Fischer von Weikersthal L · Vehling-Kaiser U · Stauch M · Quietzsch · Holch JW · Kruger S · Haas M · Michl M · von Einem J · Kirchner T · Jung A · Modest DP.

Anticancer Drugs. 2017 Aug;28(7):717-722. doi: 10.1097/CAD.0000000000000510.

Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer - FIRE-3 (AIOKRK0306).

Dominik Paul Modest · Sebastian Stintzing · [Ludwig Fischer von Weikersthal](#) · Thomas Decker · Alexander Kiani · Ursula Vehling-Kaiser · Salah-Eddin Al-Batran · Tobias Heintges · Christoph Kahl · Gernot Seipelt · Frank Kullmann · Martina Stauch · Werner Scheithauer · Swantje Held · Clemens Giessen-Jung · Andreas Jung · Thomas Kirchner · Volker Heinemann

http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3525

Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).

Modest DP · Stintzing S · [Fischer von Weikersthal L](#) · Decker T · Kiani A · Vehling-Kaiser U · Al-Batran SE · Heintges T · Lerchenmüller C · Kahl C · Seipelt G · Kullmann F · Scheithauer W · Kirchner T · Jung A · Stauch M · von Einem JC · Moehler M · Held S · Heinemann V · FIRE-3 study investigators.

Int J Cancer. 2017 Apr 15;140(8):1918-1925. doi: 10.1002/ijc.30592. Epub 2017 Feb 8.

Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.

Julian Walter Holch · Ingrid Ricard · Sebastian Stintzing · [Ludwig Fischer von Weikersthal](#) · Thomas Decker · Alexander Kiani · Ursula Vehling-Kaiser · Salah-Eddin Al-Batran · Tobias Heintges · Christian Lerchenmüller · Christoph Kahl · Frank Kullmann · Werner Scheithauer · Michael Scholz · Sebastian Müller · Hartmut Link · Andreas Rost · Heinz-Gert Höffkes · Markus Moehler · Reinhard Udo Lindig · Lisa Miller-Phillips · Thomas Kirchner · Andreas Jung · Jobst Christian von Einem · Dominik Paul Modest · Volker Heinemann

Int J Cancer. 2018 Mar 1;142(5):1047-1055. doi: 10.1002/ijc.31114. Epub 2017 Nov 7

Right-sided colorectal cancer (RC): Response to first-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR).

J. Walter Holch · S. Stintzing · S. Held · [L. Fischer von Weikersthal](#) · T. Decker · A Kiani · U. Vehling-Kaiser · S.-E. Al-Batran · T. Heintges · C. Kahl · G. Seipelt · F. Kullman · W. Scheithauer · M. Stauch · W. Scheithauer · T. Kirchner · J.C. von Einem · D. P. Modest · V. Heinemann

http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3586

2016

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

M. Michl · S. Stintzing · [L. Fischer von Weikersthal](#) · T. Decker · A Kiani · U. Vehling-Kaiser · S.-E. Al-Batran · T. Heintges · C. Lerchenmueller · C. Kahl · G. Seipelt · F. Kullmann · M. Stauch · W. Scheithauer · J. Hielscher · M. Scholz · S. Mueller · M. M. Lerch · D. P. Modest · T. Kirchner · A. Jung · V. Heinemann on behalf of the FIRE-3 Study Group

Annals of Oncology, 2016 Aug; 27(8): doi:10.1093/annonc/mdw222

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised double-blind phase 3 trial

Sebastian Stintzing · Dominik P Modest · Lisa Rossius · Marus M Lerch · Ludwig Fischer von Weikersthal · Thomas Decker · Alexander Kiani · Ursula Vehling-Kaiser · Salah-Eddin Al-Batran · Tobias Heintges · Christian Lerchenmüller · Christoph Kahl · Gernot Seipelt · Frank Kullmann · Martina Stauch · Werner Scheithauer · Swantje Held · Clemens Giessen-Jung · Markus Moehler · Andreas Jagenburg · Thomas Kirchner · Andreas Jung · Volker Heinemann · on behalf of the FIRE-3 investigators

Lancet Oncol. 2016 Oct;17(10):1426-1434. doi: 10.1016/S1470-2045(16)30269-8. Epub 2016 Aug 27

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.

Modest DP · Ricard I · Heinemann V · Hegewisch-Becker S · Schmiegel W · Porschen R · Stintzing S · Graeven U · Arnold D · von Weikersthal LF · Giessen-Jung C · Stahler A · Schmoll HJ · Jung A · Kirchner T · Tannapfel A · Reinacher-Schick A.

Ann Oncol. 2016 Sep;27(9):1746-53. doi: 10.1093/annonc/mdw261. Epub 2016 Jun 29.

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Markus Moehler · Irina Gepfner-Tuma · Annett Maderer · Peter C. Thuss-Patience · Joern Ruessel · Susanna Hegewisch-Becker · Hansjochen Wilke · Salah-Eddin Al-Batran · Mohammad-Reza Rafiyan · Florian Weißinger · Hans-Joachim Schmoll · Frank Kullmann · Ludwig Fischer von Weikersthal · Jens T. Siveke · Jens Weusmann · Stephan Kanzler · Carl Christoph Schimanski · Melanie Otte · Lukas Schollenberger · Jochem Koenig and Peter R Galle

BMC Cancer. 2016 Aug 31;16:699. doi: 10.1186/s12885-016-2736-9.

2015

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer

Dominik P Modest · Sebastian Stintzing · Ludwig Fischer von Weikersthal · Thomas Decker · Alexander Kiani · Ursula Vehling-Kaiser · Salah-Eddin Al-Batran · Tobias Heintges · Christian Lerchenmüller · Christoph Kahl · Gernot Seipelt · Frank Kullmann · Martina Stauch · Werner Scheithauer · Swantje Held · Markus Möhler · Andreas Jung · Thomas Kirchner · Volker Heinemann

Journal of Clinical Oncology 08/2015; DOI:10.1200/JCO.2015.61.2887 · 18.43 Impact Factor

Influence of mRNA expression of epiregulin (EREG) and amphiregulin (AREG) on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)

A. Stahler · V. Heinemann · C. Giessen-Jung · A. Crispin · A. Schalhorn · S. Stintzing · L. Fischer von Weikersthal · U. Vehling-Kaiser · M. Stauch · D. Quietzsch · S. Held · J.C. von Einem · J. Holch · J. Neumann · T. Kirchner · A. Jung · D.P. Modest

Int J Cancer. 2015 Aug 18. doi: 10.1002/ijc.29807 · 5.085 Impact Factor

CHAMP - A Phase II Study of Panitumumab Plus Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small Cell Lung Cancer with Particular Regard to the KRAS Status

Wolfgang Schuette · Dirk Behringer · Jan Stoehlmacher · Jens Kollmeier · Sibylle Schmager · [Ludwig Fischer von Weikersthal](#) · Christian Schumann · Joerg Buchmann

Clinical Lung Cancer 06/2015; DOI:10.1016/j.clcc.2015.05.009 · 3.22 Impact Factor

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer

Christian Eichelberg · Walter L. Vervenne · Maria De Santis · [Ludwig Fischer von Weikersthal](#) · Peter J. Goebell · Christian Lerchenmüller · Uwe Zimmermann · Monique M.E.M. Bos · Werner Freier · Silke Schirrmacher-Memmel · Michael Staehler · Sascha Pahernik · Maartje Los · Marcus Schenck · Anne Flörcken · Cornelis van Arkel · Kirsten Hauswald · Martin Indorf · Dana Gottstein · Maurice S. Michel

European Urology 05/2015; 25. DOI:10.1016/j.eururo.2015.04.017 · 12.48 Impact Factor

Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104

Stephan Kruger · Stefan Boeck · Volker Heinemann · Ruediger P Laubender · Ursula Vehling-Kaiser · Dirk Waldschmidt · Erika Kettner · Angela Märten · Cornelia Winkelmann · Stefan Klein · Georgi Kojouharoff · Thomas C Gauler · [Ludwig Fischer von Weikersthal](#) · Michael R Clemens · Michael Geissler · Tim F Greten · Susanna Hegewisch-Becker · Dominik P Modest · Sebastian Stintzing · Michael Haas

Acta oncologica (Stockholm, Sweden) 04/2015; 54(7):1-8. DOI:10.3109/0284186X.2015.1034877 · 3.71 Impact Factor

Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours

Lisa-Marie Dilz · Timm Denecke · Ingo G. Steffen · Vikas Prasad · [Ludwig Fischer von Weikersthal](#)

European journal of cancer (Oxford, England: 1990) 04/2015; 51(10). DOI:10.1016/j.ejca.2015.04.005 · 4.82 Impact Factor

2014

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann · [Ludwig Fischer von Weikersthal](#) · Thomas Decker · Alexander Kiani · Ursula Vehling-Kaiser · Salah-Eddin Al-Batran · Tobias Heintges · Christian Lerchenmüller · Christoph Kahl · Gernot Seipelt · [...] · Norbert Niederle · Andreas Rost · Heinz-Gert Höffkes · Markus Moehler · Reinhard U Lindig · Dominik P Modest · Lisa Rossius · Thomas Kirchner · Andreas Jung · Sebastian

The Lancet Oncology 07/2014; 15(10). DOI:10.1016/S1470-2045(14)70330-4 · 24.73 Impact Factor

PERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: A translational subgroup analysis from AIO-PK0104

Steffen Ormanns · Jens T Siveke · Volker Heinemann · Michael Haas · Bence Sipos · Anna Melissa Schlitter · Irene Esposito · Andreas Jung · Rüdiger P Laubender · Stephan Kruger · Ursula Vehling-Kaiser · Cornelia Winkelmann · [Ludwig Fischer von Weikersthal](#) · Michael R Clemens · Thomas C

BMC Cancer 08/2014; 14(1):624. DOI:10.1186/1471-2407-14-624 · 3.32 Impact Factor

Psychovegetative Allgemeinsymptome bei Eisenmangel ohne Anämie. General psychovegetative symptoms in iron deficiency without anaemia

von Weikersthal, LF

Chirurgische Praxis; 2014 78(2): 0009-4846

O-0018 * 2ND-LINE THERAPIES AFTER 1ST-LINE THERAPY WITH FOLFIRI IN COMBINATION WITH CETUXIMAB OR BEVACIZUMAB IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)-ANALYSIS OF THE AIO KRK 0306 (FIRE 3)- TRIAL

D. Modest · S. Stintzing · L. Fischer von Weikersthal · T. Decker · A. Kiani · U. Vehling-Kaiser · S. E. Al Batran · T. Heintges · C. Lerchenmuller · C. Kahl · G. Seipelt · F. Kullmann · M. Stauch · W. Scheithauer · S. Held · C. Giessen · A. Jung · R. Kirchner · V. Heinemann

Annals of Oncology 06/2014; 25(suppl 2):ii112-ii112. DOI:10.1093/annonc/mdu193.18 · 6.58 Impact Factor

2013

Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): Analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)

Dominik P Modest · Christoph Schulz · Ludwig Fischer von Weikersthal · Detlef Quietzsch · Jobst C von Einem · Andreas Schalhorn · Ursula Vehling-Kaiser · Rüdiger P Laubender · Clemens Giessen · Sebastian Stintzing · Volker Heinemann

Anti-cancer drugs 11/2013; 25(2). DOI:10.1097/CAD.000000000000041 · 1.89 Impact Factor

Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial

C Giessen · L Fischer von Weikersthal · R P Laubender · S Stintzing · D P Modest · A Schalhorn · C

British Journal of Cancer 08/2013; 109(6). DOI:10.1038/bjc.2013.475 · 4.82 Impact Factor

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3)

Volker Heinemann · Ludwig Fischer Weikersthal · Thomas Decker · Alexander Kiani · Ursula Vehling-Kaiser · Salah-Eddin Al-Batran · Tobias Heintges · Juergen Lerchenmueller · Christoph Kahl · Gernot Seipelt · Frank Kullmann · Martina Stauch · Werner Scheithauer · Joerg Hielscher · Michael Scholz · Sebastian Mueller · Britta Schaefer · Dominik Paul Modest · Andreas Jung · Sebastian Stintzing

J Clin Oncol 31, 2013 (suppl; abstr LBA3506)

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3)

D. Modest · L. Fischer von Weikersthal · S. Stintzing · T. Decker · A Kiani · U. Vehling-Kaiser · S.-E. Al Batran · T. Heintges · C. Lerchenmuller · C. Kahl · G. Seipelt · F. Kullmann · M. Stauch · W. Scheithauer · J. Hielscher · M. Scholz · S. Muller · B. Schafer · A Jung · V. Heinemann

Annals of Oncology 06/2013; 24(suppl 4-suppl 4):iv22-iv23. DOI:10.1093/annonc/mdt201.29 · 6.58 Impact Factor

Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial

Clemens Giessen · Ruediger Paul Laubender · [Ludwig Fischer von Weikersthal](#) · Andreas Schalhorn · Dominik Paul Modest · Sebastian Stintzing · Michael Haas · Ulrich Robert Mansmann · Volker Heinemann

Cancer Science 03/2013; 104(6). DOI:10.1111/cas.12148 · 3.53 Impact Factor

2012

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: Translational results from the randomised, crossover phase 3 trial AIO-PK0104

S Boeck · A Jung · R P Laubender · J Neumann · R Egg · C Goritschan · U Vehling-Kaiser · C Winkelmann · [L Fischer von Weikersthal](#) · M R Clemens · T C Gauler · A Märten · S Klein · G Kojouharoff · M Barner · M Geissler · T F Greten · U Mansmann · T Kirchner · V Heinemann

British Journal of Cancer 11/2012; 108(2). DOI:10.1038/bjc.2012.495 · 4.82 Impact Factor

Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer

R-D Hofheinz · V Heinemann · [L Fischer von Weikersthal](#) · R P Laubender · D Gencer · I Burkholder · A Hochhaus · S Stintzing

British Journal of Cancer 10/2012; 107(10). DOI:10.1038/bjc.2012.434 · 4.82 Impact Factor

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)

Volker Heinemann · Ursula Vehling-Kaiser · Dirk Waldschmidt · Erika Kettner · Angela Märten · Cornelia Winkelmann · Stefan Klein · Georgi Kojouharoff · Thomas C Gauler · [Ludwig Fischer von Weikersthal](#) · [...] · Michael Geissler · Tim F Greten · Susanna Hegewisch-Becker · Oleg Rubanov · Gerold Baake · Thomas Höhler · Yon D Ko · Andreas Jung · Sascha Neugebauer · Stefan Boeck

Gut 07/2012; 62(5). DOI:10.1136/gutjnl-2012-302759 · 13.32 Impact Factor

A giant neuroendocrine tumor of the thymus gland causing superior vena cava syndrome

Satsuki Komoda · Takeshi Komoda · Christoph Knosalla · Marianne E Pavel · Lars Morawietz · [Ludwig Fischer von Weikersthal](#) · Hans B Lehmkuhl · Roland Hetzer

General Thoracic and Cardiovascular Surgery 05/2012; DOI:10.1007/s11748-012-0104-5

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: Mutated tumours in the randomised German AIO study KRK-0306

S Stintzing · [L. Fischer von Weikersthal](#) · T Decker · U Vehling-Kaiser · E Jäger · T Heintges · C Stoll · C Giessen · D P Modest · J Neumann · A Jung · T Kirchner · W Scheithauer · V Heinemann

Annals of Oncology 01/2012; 23(7):1693-9. DOI:10.1093/annonc/mdr571 · 6.58 Impact Factor

2011

Randomized Phase III Trial of Docetaxel Plus Carboplatin with or without Levofloxacin Prophylaxis in Elderly Patients with Advanced Non-small Cell Lung Cancer The APRONTA Trial

Wolfgang Schuette · Sylke Nagel · [Ludwig Fischer von Weikersthal](#) · Stefan Pabst · Christian Schumann · Burkhard Deuss · Thorsten Salm · Katrin Roscher · Nicolas Dickgreber

Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 11/2011; 6(12):2090-6. DOI:10.1097/JTO.0b013e3182307e3c · 5.80 Impact Factor

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

Clemens Giessen · Ludwig Fischer von Weikersthal · Axel Hinke · Sebastian Stintzing · Frank Kullmann · Ursula Vehling-Kaiser · Julia Mayerle · Markus Bangerter · Claudio Denzlinger · Markus Sieber · Christian Teschendorf · Jens Freiberg-Richter · Christoph Schulz · Dominik Paul Modest · Nicolas Moosmann · Philipp Aubele · Volker Heinemann

BMC Cancer 08/2011; 11:367. DOI:10.1186/1471-2407-11-367 · 3.32 Impact Factor

A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer

A Schmittel · M Sebastian · L. Fischer von Weikersthal · P Martus · T C Gauler · C Kaufmann · P Hortig · J R Fischer · H Link · D Binder · B Fischer · K Caca · W E E Eberhardt · U Keilholz

Annals of Oncology 07/2011; 22(8):1798-804. DOI:10.1093/annonc/mdq652 · 6.58 Impact Factor

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: Results from the German AIO KRK-0104 trial

S Stintzing · L. Fischer von Weikersthal · U Vehling-Kaiser · M Stauch · H G Hass · H Dietzfelbinger · D Oruzio · S Klein · K Zellmann · T Decker · M Schulze · W Abenhardt · G Puchtler · H Kappauf · J Mittermüller · C Haberl · C Giessen · N Moosmann · V Heinemann

British Journal of Cancer 07/2011; 105(2):206-11. DOI:10.1038/bjc.2011.227 · 4.82 Impact Factor

Analysis for Prognostic Factors of 60-day Mortality: Evaluation of an Irinotecan-Based Phase III Trial Performed in the First-Line Treatment of Metastatic Colorectal Cancer

Clemens Giessen · Sebastian Stintzing · Ruediger Paul Laubender · Donna Pauler Ankerst · Christoph Schulz · Nicolas Moosmann · Dominik Paul Modest · Andreas Schalhorn · Ludwig Fischer von Weikersthal · Volker Heinemann

Clinical Colorectal Cancer 05/2011; 10(4):317-24. DOI:10.1016/j.clcc.2011.03.027 · 2.91 Impact Factor

Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104-A Randomized Trial of the German AIO CRC Study Group

Nicolas Moosmann · Ludwig Fischer von Weikersthal · Ursula Vehling-Kaiser · Martina Stauch · Holger G Hass · Herrmann Dietzfelbinger · Daniel Oruzio · Stefan Klein · Klaus Zellmann · Thomas Decker · Mathias Schulze · Wolfgang Abenhardt · Gerhard Puchtler · Herbert Kappauf · Johann Mittermüller · Christopher Haberl · Andreas Schalhorn · Andreas Jung · Sebastian Stintzing · Volker Heinemann

Journal of Clinical Oncology 02/2011; 29(8):1050-8. DOI:10.1200/JCO.2010.31.1936 · 18.43 Impact Factor

2010

Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer

Ludwig Fischer von Weikersthal · Andreas Schalhorn · Martina Stauch · Detlef Quietzsch · Peter A Maubach · Helmut Lambertz · Daniel Oruzio · Rudolf Schlag · Karin Weigang-Köhler · Ute Vehling-Kaiser · Manfred Schulze ·

Juergen Truckenbrodt · Mariele Goebeler · Johann Mittermüller · Daniel Bosse · Borika Szukics · Marc Grundeis · Thomas Zwingers · Clemens Giessen · Volker Heinemann

European journal of cancer (Oxford, England: 1990) 10/2010; 47(2):206-14. DOI:10.1016/j.ejca.2010.09.022 · 4.82 Impact Factor

2009

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: An interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'

Stefan Boeck · Ursula Vehling-Kaiser · Dirk Waldschmidt · Erika Kettner · Angela Märten · Cornelia Winkelmann · Stefan Klein · Georgi Kojouharoff · Thomas Gauler · Ludwig Fischer von Weikersthal · Michael R Clemens · Michael Geissler · Tim F Greten · Susanna Hegewisch-Becker · Sascha Neugebauer · Volker Heinemann

Anti-cancer drugs 09/2009; 21(1):94-100. DOI:10.1097/CAD.0b013e32833123ed · 1.89 Impact Factor

2008

Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer. Results of a phase II study in elderly patients or patients with impaired performance status.

K Abbrederis · S Lorenzen · L Fischer von Weikersthal · U Vehling-Kaiser · T Schuster · N Rothling · C Peschel · F Lordick

Critical Reviews in Oncology/Hematology 04/2008; 66(1):84-90. DOI:10.1016/j.critrevonc.2007.12.001 · 4.05 Impact Factor

2006

Randomized, Multicenter, Open-Label Phase II Study of Gemcitabine plus Single-Dose Versus Split-Dose Carboplatin in the Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer

Wolfgang Schuette · Thomas Blankenburg · Claus-Peter Schneider · Ludwig Fischer von Weikersthal · Sylvia Guetz · Gerhard Laier-Groeneveld · Johann Christian Virchow · Assnad Chemaissani · Martin

Clinical Lung Cancer 10/2006; 8(2):135-9. DOI:10.3816/CLC.2006.n.042 · 3.22 Impact Factor

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer

A Schmittel · L Fischer von Weikersthal · M Sebastian · P Martus · K Schulze · P Hortig · M Reeb · E Thiel · U Keilholz

Annals of Oncology 05/2006; 17(4):663-7. DOI:10.1093/annonc/mdj137 · 6.58 Impact Factor

2005

Phase III Study of Second-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel

Wolfgang Schuette · Sylke Nagel · Thomas Blankenburg · Christine Lautenschlaeger · Klaus Hans · Ernst-Wilhelm Schmidt · Ina Dittrich · Hans Schweisfurth · Ludwig Fischer von Weikersthal · Aruna Raghavachar · Angelika Reissig · Monika Serke

Journal of Clinical Oncology 11/2005; 23(33):8389-95. DOI:10.1200/JCO.2005.02.3739 · 18.43

Impact Factor P-563 Splitted dose carboplatin (CARBO) in comparison with singledose carboplatin in a gemcitabine(GEM)/Carboplatin schedule for stage IIIb and IV non-small cell lung cancer (NSCLC) — a randomised multi-centre phase II trial

M. Reck · S. Nagel · S. Goetz · H. Reichardt · L. Fischer v. Weikersthal · C. Schneider · G. Laier-Groenefeld · T. Fink · W. Schuette

Lung Cancer 07/2005; 49. DOI:10.1016/S0169-5002(05)81056-6 · 3.74 Impact Factor

2004

Psychovegetative Allgemeinsymptome bei Eisenmangel ohne Anämie. General psychovegetative symptoms in iron deficiency without anaemia

von Weikersthal, LF

Gynäkologische Praxis; 2004

2000

Oral Trofosfamide in Elderly and/or Heavily Pretreated Patients with Metastatic Lung Cancer

V. Horvath · A. Bakhshandeh · J.H. Hartlapp · S. Hegewisch-Becker · T. Feyerabend · L. Fischer v. Weikersthal · H.J. Illiger · E. Jäger · S.O. Peters · P. Reichardt · D. Uthgenannt · D. Weber

Onkologie 08/2000; 23(4):341-344. DOI:10.1159/000027167 · 0.84 Impact Factor